Guus Fons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guus Fons has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Jacobus van der Velden
4 shared publicationsA.C. Ansink
1 shared publicationA.G.J. van der Zee
1 shared publicationB ter Rahe
1 shared publicationFiebo J W Ten Kate
1 shared publicationFiebo J. Ten Kate
1 shared publication
Latest Publications
- 1 October 2009
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 19 (7) , 1276-1280
Prognostic Value of Bilateral Positive Nodes in Squamous Cell Cancer of the Vulva
- 1 October 2009
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 19 (7) , 1276-1280
Prognostic Value of Bilateral Positive Nodes in Squamous Cell Cancer of the Vulva
- 1 August 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 114 (2) , 343-345
Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial
- 1 August 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 114 (2) , 343-345
Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial
- 1 April 2009
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 19 (4) , 756-760
Assessment of Promising Protein Markers for Vulva Cancer
- 1 April 2009
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 19 (4) , 756-760
Assessment of Promising Protein Markers for Vulva Cancer
- 1 January 2009
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 28 (1) , 76-82
Validation of Tissue Microarray Technology in Vulvar Cancer
The aim of the study was to validate tissue microarray (TMA) for vulvar cancer by comparing immunohistochemical staining results of triplicate core biopsies on TMA with the results of full section analysis. The study material consisted of slides and selected tissue blocks from 40 patients with vulvar cancer. A TMA was constructed with 3 cores/case. Both the TMA and the slides were stained with the same antibodies against COX-2, Caspase-3, epidermal growth factor receptor, p16INK4, Cyclin D1, and Ki67. For COX-2, 2 different scoring systems were applied. Agreement in the readings between TMA and slides was expressed in total agreement and kappa. Expression patterns of antibodies can be reproduced on TMA with good reliability (kappa 0.68 to 0.75) for Ki-67, p16INK4, COX-2, Cyclin D1, and epidermal growth factor receptor in comparison with whole slides. For Caspase-3 agreement is only slight with a kappa of 0.40. The majority of discordant cases for COX-2 and Ki67 were negative on slide and positive on TMA. For epidermal growth factor receptor and Caspase-3 an opposite pattern was found. For COX-2, the use of an alternative scoring system resulted in a decrease of kappa from 0.68 to 0.21. Agreement between results on TMA and slides depends on the distribution of the protein in the cancer tissue and on the scoring system used.
- 1 January 2009
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 28 (1) , 76-82
Validation of Tissue Microarray Technology in Vulvar Cancer
The aim of the study was to validate tissue microarray (TMA) for vulvar cancer by comparing immunohistochemical staining results of triplicate core biopsies on TMA with the results of full section analysis. The study material consisted of slides and selected tissue blocks from 40 patients with vulvar cancer. A TMA was constructed with 3 cores/case. Both the TMA and the slides were stained with the same antibodies against COX-2, Caspase-3, epidermal growth factor receptor, p16INK4, Cyclin D1, and Ki67. For COX-2, 2 different scoring systems were applied. Agreement in the readings between TMA and slides was expressed in total agreement and kappa. Expression patterns of antibodies can be reproduced on TMA with good reliability (kappa 0.68 to 0.75) for Ki-67, p16INK4, COX-2, Cyclin D1, and epidermal growth factor receptor in comparison with whole slides. For Caspase-3 agreement is only slight with a kappa of 0.40. The majority of discordant cases for COX-2 and Ki67 were negative on slide and positive on TMA. For epidermal growth factor receptor and Caspase-3 an opposite pattern was found. For COX-2, the use of an alternative scoring system resulted in a decrease of kappa from 0.68 to 0.21. Agreement between results on TMA and slides depends on the distribution of the protein in the cancer tissue and on the scoring system used.
- 1 April 2007
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 26 (2) , 188-193
Identification of Potential Prognostic Markers for Vulvar Cancer Using Immunohistochemical Staining of Tissue Microarrays
The aim of this study is to determine immunohistochemical markers with prognostic significance for disease-specific survival in patients with squamous cell cancer of the vulva. The study material consisted of slides and paraffin blocks of 50 vulvectomy specimens. A tissue microarray was constructed and stained with 16 antibodies. The impact of lymph node metastases, size of tumor, vascular space involvement, and the marker expression on disease-specific survival was calculated. In univariate analysis lymph node metastases, tumor size more than 4 cm, vascular space involvement, strong cyclooxygenase 2 expression, and absent Caspase 3 expression were significantly associated with disease-specific survival. In a multivariate analysis, poor disease-specific survival is independently associated with absent Caspase 3 expression (hazard ratio, 0.2; 95% confidence interval, 0.04-0.97; P = 0.045). Five-year survival was 86% in patients with tumors positive for Caspase 3 (n = 20) and drops to 64% in patients with Caspase 3-negative tumors (n = 30). In this test set, cyclooxygenase 2 and Caspase 3 seem to be immunohistochemical markers with prognostic significance for vulva cancer. The results have to be validated.
- 1 April 2007
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 26 (2) , 188-193
Identification of Potential Prognostic Markers for Vulvar Cancer Using Immunohistochemical Staining of Tissue Microarrays
The aim of this study is to determine immunohistochemical markers with prognostic significance for disease-specific survival in patients with squamous cell cancer of the vulva. The study material consisted of slides and paraffin blocks of 50 vulvectomy specimens. A tissue microarray was constructed and stained with 16 antibodies. The impact of lymph node metastases, size of tumor, vascular space involvement, and the marker expression on disease-specific survival was calculated. In univariate analysis lymph node metastases, tumor size more than 4 cm, vascular space involvement, strong cyclooxygenase 2 expression, and absent Caspase 3 expression were significantly associated with disease-specific survival. In a multivariate analysis, poor disease-specific survival is independently associated with absent Caspase 3 expression (hazard ratio, 0.2; 95% confidence interval, 0.04-0.97; P = 0.045). Five-year survival was 86% in patients with tumors positive for Caspase 3 (n = 20) and drops to 64% in patients with Caspase 3-negative tumors (n = 30). In this test set, cyclooxygenase 2 and Caspase 3 seem to be immunohistochemical markers with prognostic significance for vulva cancer. The results have to be validated.
- 5 July 2006
- Published by BMJ in Journal of Clinical Pathology
- Vol. 60 (5) , 500-503
Validation of tissue microarray technology in endometrioid cancer of the endometrium
Aim: To validate tissue microarray (TMA) for endometrial cancer by comparing immunohistochemical staining results of triplicate core biopsies on TMA with the results of full-section analysis. Methods: The study material consisted of slides and selected tissue blocks of 41 patients with endometrioid cancer of the endometrium. A TMA was constructed. Both the TMA and the slides were stained with the same antibodies against progesterone receptor (PR), oestrogen receptor, p53 and epithelial membrane antigen (EMA). Concordance between results was expressed as the κ statistic. Results: Concordance between the staining results of TMA and whole slides was good for PR (κ = 0.69), oestrogen receptor (κ = 0.78), p53 (κ = 0.81) and EMA (κ = 0.72). Concordance between the results on TMA and slides depends on the number of assessable cores per tumour. Three assessable cores per case result in outcomes that are at least 94% similar to those achieved using conventional tissue sections with a two-class scoring system. This is independent of focal or diffuse staining patterns. Conclusion: TMA is a useful tool for further analysis of the molecular pathways in endometrial cancer. The effect of selection has to be taken into account when the prognostic value of protein expression on TMA is determined.
- 5 July 2006
- Published by BMJ in Journal of Clinical Pathology
- Vol. 60 (5) , 500-503
Validation of tissue microarray technology in endometrioid cancer of the endometrium
Aim: To validate tissue microarray (TMA) for endometrial cancer by comparing immunohistochemical staining results of triplicate core biopsies on TMA with the results of full-section analysis. Methods: The study material consisted of slides and selected tissue blocks of 41 patients with endometrioid cancer of the endometrium. A TMA was constructed. Both the TMA and the slides were stained with the same antibodies against progesterone receptor (PR), oestrogen receptor, p53 and epithelial membrane antigen (EMA). Concordance between results was expressed as the κ statistic. Results: Concordance between the staining results of TMA and whole slides was good for PR (κ = 0.69), oestrogen receptor (κ = 0.78), p53 (κ = 0.81) and EMA (κ = 0.72). Concordance between the results on TMA and slides depends on the number of assessable cores per tumour. Three assessable cores per case result in outcomes that are at least 94% similar to those achieved using conventional tissue sections with a two-class scoring system. This is independent of focal or diffuse staining patterns. Conclusion: TMA is a useful tool for further analysis of the molecular pathways in endometrial cancer. The effect of selection has to be taken into account when the prognostic value of protein expression on TMA is determined.